Angitia Australia

Angitia Biopharmaceuticals is a clinical-stage biotechnology company specializing in the development of novel therapeutics for serious musculoskeletal disorders. The company's research focuses on bone, joint, and muscle diseases with high unmet medical needs, utilizing a deep understanding of bone biology and regenerative medicine. Angitia's lead candidate, AGA2118, is a monoclonal antibody targeting sclerostin for the treatment of Osteogenesis Imperfecta, currently in clinical development. Another key program, AGA111, is designed to facilitate bone healing in spinal fusion and complex fractures. With operations spanning China, Australia, and the United States, the company is backed by prominent life science investors and aims to transform the treatment landscape for rare and common bone diseases.